Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine
Treatment and conditionWhere it standsTrials
Quality-of-Life Assessment + Questionnaire Administration + Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine for pulmonary disease, chronic obstructivePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1